404 related articles for article (PubMed ID: 17716944)
1. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
3. CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii.
Kringel H; Dubey JP; Beshah E; Hecker R; Urban JF
Vet Parasitol; 2004 Aug; 123(1-2):55-66. PubMed ID: 15265571
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
6. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection.
Sánchez VR; Pitkowski MN; Fernández Cuppari AV; Rodríguez FM; Fenoy IM; Frank FM; Goldman A; Corral RS; Martin V
Exp Parasitol; 2011 Aug; 128(4):448-53. PubMed ID: 21554876
[TBL] [Abstract][Full Text] [Related]
7. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii.
Saavedra R; Leyva R; Tenorio EP; Haces ML; Rodríguez-Sosa M; Terrazas LI; Hérion P
Parasite Immunol; 2004 Feb; 26(2):67-73. PubMed ID: 15225293
[TBL] [Abstract][Full Text] [Related]
8. CpG-ODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice.
Ribeiro DP; Freitas MM; Cardoso MR; Pajuaba AC; Silva NM; Mineo TW; Silva JS; Mineo JR; Silva DA
Vaccine; 2009 Apr; 27(19):2570-9. PubMed ID: 19428863
[TBL] [Abstract][Full Text] [Related]
9. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.
Barrier M; Lacroix-Lamandé S; Mancassola R; Auray G; Bernardet N; Chaussé AM; Uematsu S; Akira S; Laurent F
J Infect Dis; 2006 May; 193(10):1400-7. PubMed ID: 16619188
[TBL] [Abstract][Full Text] [Related]
10. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice.
El-Malky M; Shaohong L; Kumagai T; Yabu Y; Noureldin MS; Saudy N; Maruyama H; Ohta N
Microbiol Immunol; 2005; 49(7):639-46. PubMed ID: 16034207
[TBL] [Abstract][Full Text] [Related]
12. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the adjuvant properties of Astragalus membranaceus and Scutellaria baicalensis GEORGI in the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.
Yang X; Huang S; Chen J; Song N; Wang L; Zhang Z; Deng G; Zheng H; Zhu XQ; Lu F
Vaccine; 2010 Jan; 28(3):737-43. PubMed ID: 19887128
[TBL] [Abstract][Full Text] [Related]
14. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
Slotta JE; Scheuer C; Menger MD; Vollmar B
J Hepatol; 2006 Mar; 44(3):576-85. PubMed ID: 16310279
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effects of bacillus Calmette-Guerin DNA or CpG-oligonucleotide in the immune response to Taenia solium cysticercosis vaccine in porcine.
Guo YJ; Wu D; Wang KY; Sun SH
Scand J Immunol; 2007 Dec; 66(6):619-27. PubMed ID: 18021362
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
Stacey KJ; Blackwell JM
Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
[TBL] [Abstract][Full Text] [Related]
19. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
20. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
